News

XNK Therapeutics AB ("XNK") announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its leading investigational drug candidate in…
Read More...

Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2…
Read More...

Ionis Pharmaceuticals, Inc. and its wholly owned subsidiary Akcea Therapeutics, Inc., announced that Pfizer Inc. has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in…
Read More...

GW Pharmaceuticals plc announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity. Nabiximols,…
Read More...

ACG, a leading supplier of integrated pharmaceutical manufacturing solutions announced acquisition of a significant stake in Mumbai-based start-up IQGEN-X. IQGEN-X is a Contract…
Read More...

PerkinElmer, Inc. and Horizon Discovery Group plc are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will…
Read More...

Roche announced that the European Commission has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of adult patients with advanced or…
Read More...

Zucara Therapeutics Inc. a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), announced that…
Read More...

TFF Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthroughs in medicine through immune profiling,…
Read More...

Telix Pharmaceuticals Limited announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘China Grand…
Read More...

Biogen and Eisai, Co., Ltd. announced that the European Medicines Agency (EMA) has confirmed it has accepted for review, following a standard timetable, the Marketing Authorization…
Read More...

Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening…
Read More...

Novartis announced that the European Commission (EC) has approved Adakveo (crizanlizumab) for the prevention of recurrent vaso-occlusive crises (VOCs), or pain crises, in patients with…
Read More...

Protagonist Therapeutics, Inc. announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration agreement with Janssen Biotech, Inc., have been…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, confirmed that the…
Read More...

AbCellera and Kodiak Sciences Inc. announced a new partnership to generate therapeutic antibody candidates in ophthalmology. Following a previously successful collaboration, AbCellera…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational treatment for patients…
Read More...

Eli Lilly and Company announced an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for…
Read More...

Novartis and Molecular Partners AG announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19…
Read More...

CStone Pharmaceuticals announced a licensing agreement with LegoChem Biosciences, Inc. for the development and commercialization of LCB71, a potential first-in-class/best-in-class…
Read More...